A Macromolecular Janus Kinase (JAK) Inhibitor Prodrug Effectively Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice
- 66 Downloads
Tofacitinib (Tofa) has been approved for moderately to severely active ulcerative colitis (UC). To improve its therapeutic efficacy and limit dose-dependent toxicity, we developed a macromolecular prodrug of Tofa (P-Tofa). If the prodrug design improves the potency and duration of Tofa therapy, it would widen its therapeutic window, potentially leading to improved safety and better clinical management of UC.
P-Tofa was synthesized by conjugating Tofa to N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer via a cleavable carbamate linker. DSS-induced UC mouse model were treated with Tofa (daily oral gavage, from day 8), P-Tofa (single intravenous administration on day 8, dose equivalent to Tofa treatment) and saline. Healthy mice were used as a positive control. The therapeutic efficacy was evaluated using disease activity index (DAI), endoscopic score and end-point histology. The optical imaging, immunohistochemistry and flow cytometry were used to understand P-Tofa’s working mechanism.
DAI results suggested that a single dose P-Tofa treatment was more efficacious than dose equivalent daily Tofa treatment. Endoscopic evaluation and histology analyses confirmed that while both P-Tofa and Tofa protected the colon, P-Tofa treated group was observed with better colon integrity with less tissue damage. Optical imaging, flow cytometry and immunohistochemistry results showed that P-Tofa passively targeted the inflamed colon and being retained via cellular sequestration.
Single intravenous administration of P-Tofa was more effective than dose equivalent daily oral Tofa gavage in ameliorating DSS-induced colitis. This observed superior therapeutic efficacy may be attributed to P-Tofa’s passive targeting to and retention by the inflamed colon.
Key WordsELVIS inflammation targeting prodrug tofacitinib Ulcerative colitis (UC)
ACKNOWLEDGMENTS AND DISCLOSURES
This study was supported in part by the National Institute of Allergy and Infectious Diseases (R01 AI119090) of the National Institute of Health of the United States of America, and China Scholarship Council (XW, GZ, FZ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
- 2.Molodecky, N.A., et al., Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 2012. 142(1): p. 46–54. e42.Google Scholar
- 4.Loftus EV Jr. Update on the incidence and prevalence of inflammatory bowel disease in the United States. Gastroenterol Hepatol. 2016;12(11):704–7.Google Scholar
- 7.De Vries, L., et al., The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2017: p. jjx003.Google Scholar
- 8.Friedman, S., Tofacitinib for Ulcerative Colitis—A Promising Step Forward. 2017, Mass Medical Soc.Google Scholar
- 12.Chassaing, B., et al., Dextran sulfate sodium (DSS)-induced colitis in mice. Current protocols in immunology, 2014: p. 15.25. 1–15.25. 14.Google Scholar
- 13.De Vries, L., et al. The Efficacy of Tofacitinib and a Selective Janus Kinase 1 Inhibitor in Dextran Sulphate Sodium Colitis Models. in JOURNAL OF CROHNS & COLITIS. 2016. OXFORD UNIV PRESS GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND.Google Scholar
- 14.Cooper, H.S., et al., Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Laboratory investigation; a journal of technical methods and pathology, 1993. 69(2): p. 238–249.Google Scholar
- 15.Rumi G, et al. Dual role of endogenous nitric oxide in development of dextran sodium sulfate-induced colitis in rats. Journal of Physiology and Pharmacology: an Official Journal of the Polish Physiological Society. 2004;55(4):823–36.Google Scholar
- 18.Kim, C., et al., L-cysteine supplementation attenuates local inflammation and restores gut homeostasis in a porcine model of colitis. Biochimica et Biophysica Acta (BBA)-General Subjects, 2009. 1790(10): p. 1161–1169.Google Scholar
- 19.Rieder F, Fiocchi C. Intestinal fibrosis in inflammatory bowel disease—current knowledge and future perspectives. J Crohn's Colitis. 2008;2(4):279–90.Google Scholar
- 27.Wang D, Miller SC, Liu XM, Anderson B, Wang XS, Goldring SR. Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. Arthritis research & therapy. 2007;9(1):R2.Google Scholar
- 37.Low, D., D.D. Nguyen, and E. Mizoguchi, Animal models of ulcerative colitis and their application in drug research. Drug design, development and therapy, 2013. 7: p. 1341.Google Scholar